ReviewJournal of ginseng research2025
Protective effects of ginsenosides in cerebral small vessel disease: Cellular and molecular mechanisms.
Review in Journal of ginseng research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Ginseng Bioactive Components as Gut-Brain Axis-Targeted Modulators: Therapeutic Potential and Mechanisms in Multifactorial Diseases.Nutrients · 2026Pooled it
- Korean red ginseng saponins ameliorate metabolic dysfunction-associated steatohepatitis in mice by inhibiting caspase-11 and NLRP3 inflammasomes.Journal of ginseng research · 2026Article
- Ginsenosides: potential therapeutic agents against hepatic fibrosis.Journal of ginseng research · 2026Review
- A review of pharmacological properties and pharmacokinetic of 20(S)-protopanaxadiol.Journal of ginseng research · 2026Review
- Sevoflurane ameliorates cerebral ischemia-reperfusion injury by modulating mitochondrial dynamics and attenuating apoptosis via Shh-YAP1 signaling pathway.Molecular brain · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cerebral small vessel disease (CSVD), an age-related vascular disorder linked to cognitive decline, lacks targeted therapies. Ginsenosides, bioactive compounds in ginseng, demonstrate multi-target potential against CSVD by modulating neurovascular dysfunction. Experimental studies highlight their anti-inflammatory, antioxidant, and neuroprotective properties. Ginsenosides suppress pro-inflammatory cytokines (tumor necrosis factor α [TNF-α], interleukin-1β [IL-1β], IL-6) via nuclear factor-kappa B/nod-like receptor protein (NF-κB/NLRP1) inflammasome inhibition, stabilize the blood-brain barrier by preserving tight junctions and reducing matrix metalloproteinase activity, and enhance endothelial survival through vascular endothelial growth factor/sonic hedgehog (VEGF/Shh)-mediated angiogenesis. They mitigate vascular remodeling by blocking vascular smooth muscle cell (VSMC) proliferation via phosphatidylinositol 3 kinase/protein kinase B (PI3K/Akt) and mitogen-activated protein kinase (MAPK) signaling, while attenuating microglial activation and astrocyte dysfunction to improve cerebral blood flow. These compounds also alleviate oxidative stress and promote neurovascular unit integrity. Future research should focus on optimizing ginsenoside combinations, elucidating protein interactions, and exploring synergies with complementary agents to enhance therapeutic efficacy. Ginsenosides represent a promising multi-mechanistic approach for CSVD treatment, addressing inflammation, vascular pathology, and neural damage.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.